Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 382-388

  Leung, Roland ^a   Lang, Brian ^a   Wong, Hilda ^a   Chiu, Joanne ^a   Yat, Wan K ^a   Shek, Tony ^a   Cho, Woo Y ^a   Yau, Lo C ^a   Yau, Thomas ^a,b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Carcinoid; Everolimus; Neuroendocrine; Pancreatic; Sunitinib

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; LAR; LUTETIUM; OCTREOTIDE; PASIREOTIDE; PAZOPANIB; PEGINTERFERON; PLATELET DERIVED GROWTH FACTOR; PLATINUM; RAPAMYCIN; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABLATION THERAPY; ANEMIA; ARTICLE; CANCER INHIBITION; CARCINOID; CELL CYCLE PROGRESSION; CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; DEATH; DIARRHEA; DISEASE COURSE; HUMAN; HYPERGLYCEMIA; INFECTION; MOLECULAR THERAPY; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS ISLET CELL TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SKIN DISEASE; STOMATITIS; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CARCINOMA, NEUROENDOCRINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RADIOPHARMACEUTICALS; SIGNAL TRANSDUCTION; SIROLIMUS; SOMATOSTATIN; TOR SERINE-THREONINE KINASES;

EID: 84876729549     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313030002     Document Type: Article

References (43)

1. Kulke, M.H.; Siu, L.L.; Tepper, J.E.; Fisher, G.; Jaffe, D.; Haller, D.G.; Ellis, L.M.; Benedetti, J.K.; Bergsland, E.K.; Hobday, T.J.; Van Cutsem, E.; Pingpank, J.; Oberg, K.; Cohen, S.J.; Posner, M.C.; Yao, J.C. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol., 2011, 29(7), 934-943.
2. Oberg, K. Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr. Opin. Oncol., 2005, 17(4), 386-391.
3. Yao, J.C.; Hassan, M.; Phan, A.; Dagohoy, C.; Leary, C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.N.; Rashid, A.; Evans, D.B. One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol., 2008, 26(18), 3063-3072.
4. Modlin, I.M.; Oberg, K.; Chung, D.C.; Jensen, R.T.; de Herder, W.W.; Thakker, R.V.; Caplin, M.; Delle Fave, G.; Kaltsas, G.A.; Krenning, E.P.; Moss, S.F.; Nilsson, O.; Rindi, G.; Salazar, R.; Ruszniewski, P.; Sundin, A. Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol., 2008, 9(1), 61-72.
5. Sarmiento, J.M.; Heywood, G.; Rubin, J.; Ilstrup, D.M.; Nagorney, D.M.; Que, F.G. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J. Am. Coll. Surg., 2003, 197(1), 29-37.
6. Osborne, D.A.; Zervos, E.E.; Strosberg, J.; Boe, B.A.; Malafa, M.; Rosemurgy, A.S.; Yeatman, T.J.; Carey, L.; Duhaine, L.; Kvols, L.K. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors (vol 13, pg 572, 2006). Ann. Surg. Oncol., 2006, 13(8), 1162-1162.
7. Boudreaux, J.P.; Putty, B.; Frey, D.J.; Woltering, E.; Anthony, L.; Daly, I.; Ramcharan, T.; Lopera, J.; Castaneda, W.F. Surgical treatment of advanced-stage carcinoid tumors - Lessons learned. Ann. Surg., 2005, 241(6), 839-845.
8. Raut, C.P.; Kulke, M.H. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist, 2011, 16(3), 286-295.
9. Akerstrom, G.; Hellman, P.; Hessman, O.; Osmak, L. Management of midgut carcinoids. J. Surg. Oncol., 2005, 89(3), 161-169.
10. de Vries, H.; Verschueren, R.C.J.; Willemse, P.H.B.; Kema, I.P.; de Vries, E.G.E. Diagnostic, surgical and medical aspect of the midgut carcinoids. Cancer Treat. Rev., 2002, 28(1), 11-25.
11. Plockinger, U.; Rindi, G.; Arnold, R.; Eriksson, B.; Krenning, E.P.; de Herder, W.W.; Goede, A.; Caplin, M.; Wiedenmann, B.; Oberg, K.; Reubi, J.C.; Nilsson, O.; Delle Fave, G.; Ruszniewski, P.; Ahlman, H. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors - A consensus statement on behalf of the European Neuroendocrine Tumor Society (ENETS). Neuroendocrinology, 2004, 80(6), 394-424.
12. Klimstra, D.S.; Modlin, I.R.; Adsay, N.V.; Chetty, R.; Deshpande, V.; Gonen, M.; Jensen, R.T.; Kidd, M.; Kulke, M.H.; Lloyd, R.V.; Moran, C.; Moss, S.F.; Oberg, K.; O'Toole, D.; Rindi, G.; Robert, M.E.; Suster, S.; Tang, L.H.; Tzen, C.Y.; Washington, M.K.; Wiedenmann, B.; Yao, J. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am. J. Surg. Pathol., 2010, 34(3), 300-313.
13. Ambs, S.; Bennett, W.P.; Merriam, W.G.; Ogunfusika, M.O.; Oser, S.M.; Khan, M.A.; Jones, R.T.; Harris, C.C. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br. J. Cancer, 1998, 78(2), 233-239.
14. Chaudhry, A.; Papanicolaou, V.; Oberg, K.; Heldin, C.H.; Funa, K. Expression of platelet-derived growth-factor and its receptors in neuroendocrine tumors of the digestive-system. Cancer Res., 1992, 52(4), 1006-1012.
15. Christofori, G.; Naik, P.; Hanahan, D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol. Endocrinol., 1995, 9(12), 1760-1770.
16. Hopfner, M.; Baradari, V.; Huether, A.; Schofl, C.; Scherubl, H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumors. Endocr. Relat. Cancer, 2006, 13(1), 135-149.
17. La Rosa, S.; Uccella, S.; Finzi, G.; Albarello, L.; Sessa, F.; Capella, C. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: Correlation with microvessel density and clinicopathologic features. Hum. Pathol., 2003, 34(1), 18-27.
18. Lankat-Buttgereit, B.; Muller, S.; Schmidt, H.; Parhofer, K.G.; Gress, T.M.; Goke, R. Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line. Biol. Cell, 2008, 100(12), 703-715.
19. Rinke, A.; Muller, H.H.; Schade-Brittinger, C.; Klose, K.J.; Barth, P.; Wied, M.; Mayer, C.; Aminossadati, B.; Pape, U.F.; Blaker, M.; Harder, J.; Arnold, C.; Gress, T.; Arnold, R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol., 2009, 27(28), 4656-4663.
20. Oberg, K.E.; Reubi, J.C.; Kwekkeboom, D.J.; Krenning, E.P. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology, 2010, 139(3), 742-753, 753 e741.
21. Kvols, L.; Wiedenmann, B.; Oberg, K.; Glusman, J.E.; O'dorisio, T.M.; De Herder, W.; Gao, B.; Arnold, R.; Anthony, L.; The SOM230 Carcinoid Study Group. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. J. Clin. Oncol., 2006, 24(18S), 4082.
22. Virgolini, I.; Traub, T.; Novotny, C.; Leimer, M.; Fuger, B.; Li, S.R.; Patri, P.; Pangerl, T.; Angelberger, P.; Raderer, M.; Burggasser, G.; Andreae, F.; Kurtaran, A.; Dudczak, R. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr. Pharm. Des., 2002, 8(20), 1781-1807.
23. Waldherr, C.; Pless, M.; Maecke, H.R.; Schumacher, T.; Crazzolara, A.; Nitzsche, E.U.; Haldemann, A.; Mueller-Brand, J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq Y-90-DOTATOC. J. Nucl. Med., 2002, 43(5), 610-616.
24. Kwekkeboom, D.J.; Teunissen, J.J.; Bakker, W.H.; Kooij, P.P.; de Herder, W.W.; Feelders, R.A.; van Eijck, C.H.; Esser, J.P.; Kam, B.L.; Krenning, E.P. Radiolabeled somatostatin analog [Lu-177-DOTA(0),Tyr(3)] octreotate in patients with endocrine gastro-enteropancreatic tumors. J. Clin. Oncol., 2005, 23(12), 2754-2762.
25. Fingar, D.C.; Richardson, C.J.; Tee, A.R.; Cheatham, L.; Tsou, C.; Blenis, J. Mtor controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol., 2004, 24(1), 200-216.
26. Vignot, S.; Faivre, S.; Aguirre, D.; Raymond, E. MTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol., 2005, 16(4), 525-537.
27. Yao, J.C.; Phan, A.T.; Chang, D.Z.; Wolff, R.A.; Hess, K.; Gupta, S.; Jacobs, C.; Mares, J.E.; Landgraf, A.N.; Rashid, A.; Meric-Bernstam, F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol., 2008, 26(26), 4311-4318.
28. Yao, J.C.; Lombard-Bohas, C.; Baudin, E.; Kvols, L.K.; Rougier, P.; Ruszniewski, P.; Hoosen, S.; Peter, J.; Haas, T.; Lebwohl, D.; Van Cutsem, E.; Kulke, M.H.; Hobday, T.J.; O'Dorisio, T.M.; Shah, M.H.; Cadiot, G.; Luppi, G.; Posey, J.A.; Wiedenmann, B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J. Clin. Oncol., 2010, 28(1), 69-76.
29. Yao, J.C.; Shah, M.H.; Ito, T.; Bohas, C.L.; Wolin, E.M.; Van Cutsem, E.; Hobday, T.J.; Okusaka, T.; Capdevila, J.; de Vries, E.G.E.; Tomassetti, P.; Pavel, M.E.; Hoosen, S.; Haas, T.; Lincy, J.; Lebwohl, D.; Öberg, K. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364(6), 514-523.
30. Duran, I.; Kortmansky, J.; Singh, D.; Hirte, H.; Kocha, W.; Goss, G.; Le, L.; Oza, A.; Nicklee, T.; Ho, J.; Birle, D.; Pond, G.R.; Arboine, D.; Dancey, J.; Aviel-Ronen, S.; Tsao, M.S.; Hedley, D.; Siu, L.L. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer, 2006, 95(9), 1148-1154.
31. Kulke, M.H.; Lenz, H.J.; Meropol, N.J.; Posey, J.; Ryan, D.P.; Picus, J.; Bergsland, E.; Stuart, K.; Tye, L.; Huang, X.; Li, J.Z.; Baum, C.M.; Fuchs, C.S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol., 2008, 26(20), 3403-3410.
32. Kane, R.C.; Farrell, A.T.; Saber, H.; Tang, S.; Williams, G.; Jee, J.M.; Liang, C.; Booth, B.; Chidambaram, N.; Morse, D.; Sridhara, R.; Garvey, P.; Justice, R.; Pazdur, R. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res., 2006, 12(24), 7271-7278.
33. Hobday, T.J.; Rubin, J.; Holen, K.; Picus, J.; Donehower, R.; Marschke, R.; Maples, W.; Lloyd, R.; Mahoney, M.; Erlichman, C. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J. Clin. Oncol., 2007, 25(18S), 4504.
34. Epstein, R.J. VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev., 2007, 26(3-4), 443-452.
35. Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med., 2001, 7(9), 987-989.
36. Yao, J.C.; Phan, A.; Hoff, P.M.; Chen, H.X.; Charnsangavej, C.; Yeung, S.-C.J.; Hess, K.; Ng, C.; Abbruzzese, J.L.; Ajani, J.A. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J. Clin. Oncol., 2008, 26(8), 1316-1323.
37. Öberg, K.; Åkerström, G.; Rindi, G.; Jelic, S. Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2010, 21(suppl 5), v223-v227.
38. Zhao, J.; de Krijger, R.R.; Meier, D.; Speel, E.J.; Saremaslani, P.; Muletta-Feurer, S.; Matter, C.; Roth, J.; Heitz, P.U.; Komminoth, P. Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. Am. J. Pathol., 2000, 157(5), 1431-1438.
39. Jiao, Y.; Shi, C.; Edil, B.H.; de Wilde, R.F.; Klimstra, D.S.; Maitra, A.; Schulick, R.D.; Tang, L.H.; Wolfgang, C.L.; Choti, M.A.; Velculescu, V.E.; Diaz, L.A., Jr.; Vogelstein, B.; Kinzler, K.W.; Hruban, R.H.; Papadopoulos, N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 2011, 331(6021), 1199-1203.
40. Phan, A.T.; Yao, J.C.; Fogelman, D.R.; Hess, K.R.; Ng, C.S.; Bullock, S.A.; Malinowski, P.; Regan, E.; Kulke, M. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J. Clin. Oncol., 2010, 28(15_suppl), 4001.
41. Yao, J.C.; Phan, A.T.; Fogleman, D.; Ng, C.S.; Jacobs, C.B.; Dagohoy, C.D.; Leary, C.; Hess, K.R. Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J. Clin. Oncol., 2010, 28(15_suppl), 4002.
42. Raymond, E.; Dahan, L.; Raoul, J.-L.; Bang, Y.-J.; Borbath, I.; Lombard-Bohas, C.; Valle, J.; Metrakos, P.; Smith, D.; Vinik, A.; Chen, J.-S.; Hörsch, D.; Hammel, P.; Wiedenmann, B.; Van Cutsem, E.; Patyna, S.; Lu, D.R.; Blanckmeister, C.; Chao, R.; Ruszniewski, P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364(6), 501-513.
43. Yao, J.C.; Hainsworth, J.D.; Baudin, E.; Peeters, M.; Hoersch, D.; Anthony, L.B.; Klimovsky, J.; Grouss, K.; Jehl, V.; Pavel, M. Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2). J. Clin. Oncol., 2011, 29(4_suppl), 159.